Note: This document has been translated from the Japanese original for reference purposes only. In the event ofany discrepancy between this translated document and the Japanese original, the original shall prevail.

November 9, 2023
CompanyHeadquarters
Representative
Contact
Telephone
WebsiteTakara Bio Inc. (Securities code: 4974;Prime Market)
Nojihigashi 7-4-38, Kusatsu, Shiga, Japan
Koichi Nakao, President & CEO
Takuya Kakemi, Executive Officer, in chargeof PR & IR Department(+81)77-565-6970
https://www.takara-bio.co.jp/Notice Concerning Revisions to the Financial Results Forecasts

Takara Bio Inc. hereby announces that in the light of the most recent operating trends, to revise the financial results
forecasts for the fiscal year ending March 31, 2024 (April 1, 2023 – March 31, 2024), disclosed on May 11, 2023,
as described below.
1. Revisions to financial results forecasts
Revisions to consolidated financial results forecasts for the full-year of the current fiscal year (April 1, 2023
through March 31, 2024)

Net sales

OperatingprofitOrdinary
profit

Net income
attributable toowners ofthe parent

Net income
per share

Million yen

Million yen

Million yen

Million yen

Yen

53,300

8,000

8,200

5,500

45.67

Revised forecasts (B)45,500

3,000

3,200

2,000

16.61

Change (B-A)(7,800)(5,000)(5,000)(3,500)-Change (%)(14.6)(62.5)(61.0)(63.6)-(Reference)
Actualconsolidated results
for the previous fiscal
year (Fiscal year
ended March 31,2023)

78,142

20,541

20,682

16,012132.97

Previously announced
forecasts (A)(Disclosed on May
11, 2023)

(2) Reason for revision
As the global market for the life sciences in research and development is sluggish due to the effects ofprolonged inflation, economic recession, and intensifying of price competition for products and services, oursales of Reagents, Instruments, and CDMO (in Gene Analysis / Testing) business are expected to be lower
than the previous forecast. As a results, each profit item is also expected to be lower than the previous
forecast, and then the full-year consolidated financial forecasts is revised.
Please refer to page 10 of the "Consolidated Financial Results for the Six Months Ended September 30, 2023"
announced today for details of the forecasts announced this time.

Forward-Looking Statements
Statements contained in these materials with respect to the Company’s current plans, forecasts, strategies and beliefs that are
not historical facts are forward-looking statements about the further performance of the Company and its consolidated
subsidiaries. These statements are based on management’s assumptions and beliefs in light of information currently available
to it, but are based on a number of assumptions and beliefs derived from information that contains significant risks anduncertainties. Actual results may differ materially from these forecasts due to various factors. Factors that could influence
actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as
exchange rate fluctuations, changes in laws and government systems, pressure from competitors’ prices and productstrategies, declines in selling power of the Company’s existing and new products, disruptions to production, violations of ourintellectual property rights, rapid advances in technology, and unfavorable verdicts in major litigation.